I enjoyed reading an excellent
review in Science Translational Medicine
on problems and possibilities concerning therapeutic utilization of siRNA. The
authors, from MD Anderson Cancer Center, covered all the key issues including target
selection, delivery, toxicity and pharmaceutical feasibility. An interesting
sidelight for me, however, was that the article focused solely on siRNA and completely
ignored single stranded oligonucleotides such as ‘classic’ antisense or splice
switching oligonucleotides although these molecules share exactly the same prospects
and problems as siRNA. This reflects a schism of interests in the oligonucleotide
therapeutics field with one group of investigators (and companies) promoting
the virtues of siRNA while another cohort focuses on single stranded oligos. Fortunately
there are venues where the two groups can communicate- one being the annual
meeting of the Oligonucleotide Therapeutics Society where all forms of nucleic acid
therapy are considered. It’s an interesting commentary on science, however,
that even in a relatively small field a considerable amount of parochialism can
come into play.
http://www.oligotherapeutics.org/
No comments:
Post a Comment